In the third quarter of 2012 research and development expenses were $11.7 million dollars as compared to $10.8 million dollars for the same period of 2011. Third quarter general and administrative expenses were $2.8 million dollars as compared to $3.1 million dollars for the comparable period in 2011.In the third quarter of 2012 the Company’s net loss was $15.0 million dollars or $0.25 cents per basic and diluted share as compared to a net loss of $12.7 million dollars or $0.26 cents per basic and diluted share in the same period of 2011.
Synta Provides Clinical Update And Reports Third Quarter 2012 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.